First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Phase 1 Active not recruiting 184 enrolled Amgen

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.

Timeline

Start: 2022-08-24
Primary completion: 2028-08-28
Completion: 2028-08-28

Publications

Background Paulson KG, Lau SCM, Ahn MJ, Moskovitz M, Pogorzelski M, Hafliger S, Parkes A, Zhang Y, Hamidi A, Thompson CG, Wermke M. Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study. Lancet Oncol. 2025 Oct;26(10):1300-1311. doi: 10.1016/S1470-2045(25)00480-2. Epub 2025 Sep 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atezolizumab	Monoclonal antibody	—	Intravenous
Subject	Carboplatin	Small molecule	—	Intravenous
Subject	Durvalumab	Monoclonal antibody	—	Intravenous
Subject	Etoposide	Small molecule	—	Intravenous
Subject	Tarlatamab	Protein / enzyme biologic	—	Intravenous

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Summary

Timeline

Publications

Drugs

Indications